Mizuho Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price

CVS Health (NYSE:CVS) had its price objective upped by Mizuho from $88.00 to $95.00 in a report issued on Wednesday morning, MarketBeat reports. Mizuho currently has an outperform rating on the pharmacy operator’s stock.

Other research analysts have also issued research reports about the stock. Barclays raised their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird boosted their price objective on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a research note on Wednesday. Leerink Partners upped their price objective on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Raymond James Financial lifted their target price on CVS Health from $75.00 to $90.00 in a report on Friday, October 31st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $99.00) on shares of CVS Health in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $93.24.

CVS Health Stock Performance

Shares of CVS opened at $79.08 on Wednesday. The stock has a market capitalization of $100.39 billion, a PE ratio of 208.12, a price-to-earnings-growth ratio of 0.76 and a beta of 0.48. The business’s fifty day moving average price is $78.87 and its 200 day moving average price is $71.64. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. CVS Health has a 12-month low of $43.56 and a 12-month high of $85.15.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Equities research analysts forecast that CVS Health will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is presently 700.00%.

Institutional Trading of CVS Health

Several large investors have recently made changes to their positions in CVS. SOA Wealth Advisors LLC. lifted its position in CVS Health by 36.9% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after acquiring an additional 131 shares during the last quarter. Alteri Wealth LLC increased its stake in shares of CVS Health by 3.2% in the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after purchasing an additional 131 shares during the period. Holistic Financial Partners increased its stake in shares of CVS Health by 4.1% in the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock worth $256,000 after purchasing an additional 133 shares during the period. CYBER HORNET ETFs LLC boosted its stake in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares during the period. Finally, Fayez Sarofim & Co boosted its stake in CVS Health by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 6,913 shares of the pharmacy operator’s stock valued at $521,000 after purchasing an additional 140 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.